Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Bio and partner RemeGen have received conditional approval from China's NMPA for telitacicept to treat adult patients with IgA nephropathy (IgAN), marking the first BAFF/APRIL-targeting therapy approved for this condition. The approval is supported by positive Phase 2 and Phase 3 data showing significant reduction in proteinuria and preservatio…